These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26712326)

  • 1. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.
    Feenstra MGP; Klompmakers A; Figee M; Fluitman S; Vulink N; Westenberg HGM; Denys D
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):310-319. PubMed ID: 26712326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.
    Denys D; Klompmakers AA; Westenberg HG
    Psychopharmacology (Berl); 2004 Nov; 176(2):195-203. PubMed ID: 15138756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
    Ago Y; Nakamura S; Baba A; Matsuda T
    Neuropsychopharmacology; 2005 Jan; 30(1):43-51. PubMed ID: 15383832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
    Metin O; Yazici K; Tot S; Yazici AE
    Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
    Bruno A; Pandolfo G; Cedro C; Gallo G; De Felice M; Zoccali RA; Muscatello MR
    Clin Neuropharmacol; 2016; 39(1):6-9. PubMed ID: 26757309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
    McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
    J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
    Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
    J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.